Via practica 11/2009
Overview of results in selected pharmacoeconomic studies with valsartan
Heart failure and post-IM therapy are the key therapeutic areas where valsartan has its’ economic analysis and evaluations. From economic and costs perspective, valsartan has confirmed its position in patients with heart failure (without ACE inhibitors baseline treatment) and patients after IM not suitable for treatment with ACE inhibitor.
Keywords: valsartan, pharmacoeconomy, costs, heart failure, myocardial infarction
